Shares are trading at $0.65 quite a bit higher than the 50 day moving average of $0.57 and which is slightly below the 200 day moving average of $0.68. The 50 day moving average was up $0.08 whereas the 200 day average was down by -4.78%. Trading volume for ContraVir Pharmaceuticals Inc was 18K by the end of trading on Tuesday. Shares saw a steep decrease in trading volume of 96.87% under the normal average daily volume.
Investors are a little more bullish on ContraVir Pharmaceuticals Inc lately if you put credence in the motion in short interest. The stock realized a fall in short interest of -37.41% between September 15, 2017 and September 29, 2017. Short shares fell 2,216,332 over that timeframe. With short interest at 3,707,842 and short average daily volume at 610,983, days to cover is 6.0 and the percentage of shorted shares was 0.06% on September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (CTRV). Cambridge Investment Research Advisors, Inc. cut its position by shedding 1,970 shares a decrease of 11.7% from 03/31/2017 to 06/30/2017. Cambridge Investment Research Advisors, Inc. controls 14,870 shares worth $9,000. The total value of its holdings decreased 70.0%. Creative Planning downsized its ownership by selling 557 shares a decrease of 31.5% as of 06/30/2017. Creative Planning now controls 1,212 shares with a value of $1,000. The value of the position overall is down by 66.7%.
Prospera Financial Services Inc added to its holdings by buying 500 shares an increase of 0.3%. Prospera Financial Services Inc now holds 167,600 shares valued at $126,000. The total value of its holdings increased 27.3%. As of quarter end Bank Of Montreal /can/ had sold a total of 30,000 shares trimming its position 37.5%. The value in dollars went from $46,000 to $26,000 decreasing 43.5% quarter over quarter.
In the latest earnings report the EPS was $-0.30 and is estimated to be $-0.37 for the current year with 78,001,000 shares outstanding. Next quarter’s EPS is expected be $-0.08 and the next full year EPS is projected to be $-0.37.
ContraVir Pharmaceuticals, Inc., launched on May 15, 2013, is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100..